SEC Form 4 · accession 0001607062-18-000350
GENEREX BIOTECHNOLOGY CORP · GNBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard David Purcell Jr.
Officer — SVP of Research & Drug Develop · Director
Period of report
Oct 3, 2018
Accepted (ET)
Oct 15, 2018 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001059784
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.23 | Oct 3, 2018 | A | 4,500 | A | — | Oct 3, 2028 | Common Stock | 4,500 | 4,500 | D |
Explanation of responses
- F1The option vests in three equal annual installments beginning on October 3, 2018.